JC
Jashvantkumar Chunilal Patel
About Jashvantkumar Chunilal Patel
Data last updated:
Jashvantkumar Chunilal Patel has 4 years in corporate governance. Holds Additional Director role. Currently with 1 company, including Ancil Pharma Private Limited. Engaged in General Business. Contributes to corporate operations. The largest current company by reported revenue is Ancil Pharma Private Limited at ₹10.57 Cr (FY 2025).
Current companies
| Company | Designation | Appointment | Founded | Revenue | Status |
|---|---|---|---|---|---|
 Ancil Pharma Private Limited U51397GJ2019PTC111192 | Additional Director | 06 Apr 2022 | 2019 | ₹10.57 Cr (FY 2025) | Active |
Previous companies
Explore Director's current and past company associations Uncover their professional journey today!
Directorship timeline
Open interactive timeline →Shareholding and investment profile for Jashvantkumar Chunilal Patel
Company-level share counts, filed values, and quarterly changes require authenticated premium access.
- Company-level holdings
- Filed share counts
- Reported values
- Quarterly changes
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Jashvantkumar Chunilal Patel
Jashvantkumar Chunilal Patel has 4 years in corporate governance. Holds Additional Director role. Currently with 1 company, including Ancil Pharma Private Limited. Engaged in General Business. Contributes to corporate operations. The largest current company by reported revenue is Ancil Pharma Private Limited at ₹10.57 Cr (FY 2025).
Jashvantkumar Chunilal Patel is associated with 1 company as Additional Director, including Ancil Pharma Private Limited (₹10.57 Cr).
Jashvantkumar Chunilal Patel has expertise in General Business.
Jashvantkumar Chunilal Patel has 4 years in corporate governance.
By reported revenue, the largest current company of Jashvantkumar Chunilal Patel is Ancil Pharma Private Limited, with revenue of ₹10.57 Cr (FY 2025).
Jashvantkumar Chunilal Patel currently holds positions at 1 company: Ancil Pharma Private Limited (₹10.57 Cr).